| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
1 | AN ACT concerning health.
| |||||||||||||||||||||||||
2 | Be it enacted by the People of the State of Illinois,
| |||||||||||||||||||||||||
3 | represented in the General Assembly:
| |||||||||||||||||||||||||
4 | Section 5. The Overdose Prevention and Harm Reduction Act | |||||||||||||||||||||||||
5 | is amended by changing Section 5 and by adding Sections 10, 15, | |||||||||||||||||||||||||
6 | and 20 as follows: | |||||||||||||||||||||||||
7 | (410 ILCS 710/5)
| |||||||||||||||||||||||||
8 | Sec. 5. Needle and hypodermic syringe access program. | |||||||||||||||||||||||||
9 | (a) Any governmental or nongovernmental organization, | |||||||||||||||||||||||||
10 | including a local health department, community-based | |||||||||||||||||||||||||
11 | organization, or a person or entity, that promotes | |||||||||||||||||||||||||
12 | scientifically proven ways of mitigating health risks | |||||||||||||||||||||||||
13 | associated with drug use and other high-risk behaviors may | |||||||||||||||||||||||||
14 | establish and operate a needle and hypodermic syringe access | |||||||||||||||||||||||||
15 | program. The objective of the program shall be accomplishing | |||||||||||||||||||||||||
16 | all of the following: | |||||||||||||||||||||||||
17 | (1) reducing the spread of HIV, AIDS, viral hepatitis, | |||||||||||||||||||||||||
18 | and other bloodborne diseases; | |||||||||||||||||||||||||
19 | (2) reducing the potential for needle stick injuries | |||||||||||||||||||||||||
20 | from discarded contaminated equipment; and | |||||||||||||||||||||||||
21 | (3) facilitating connections or linkages to | |||||||||||||||||||||||||
22 | evidence-based treatment.
| |||||||||||||||||||||||||
23 | (b) Programs established under this Act shall provide all |
| |||||||
| |||||||
1 | of the following: | ||||||
2 | (1) Disposal of used needles and hypodermic syringes. | ||||||
3 | (2) Needles, hypodermic syringes, and other safer drug | ||||||
4 | consumption supplies, at no cost and in quantities | ||||||
5 | sufficient to ensure that needles, hypodermic syringes, or | ||||||
6 | other supplies are not shared or reused. | ||||||
7 | (3) Educational materials or training on: | ||||||
8 | (A) overdose prevention and intervention; and | ||||||
9 | (B) the prevention of HIV, AIDS, viral hepatitis, | ||||||
10 | and other common bloodborne diseases resulting from | ||||||
11 | shared drug consumption equipment and supplies. | ||||||
12 | (4) Access to opioid antagonists approved for the | ||||||
13 | reversal of an opioid overdose, or referrals to programs | ||||||
14 | that provide access to opioid antagonists approved for the | ||||||
15 | reversal of an opioid overdose.
| ||||||
16 | (5) Linkages to needed services, including mental | ||||||
17 | health treatment, housing programs, substance use disorder | ||||||
18 | treatment, and other relevant community services. | ||||||
19 | (6) Individual consultations from a trained employee | ||||||
20 | tailored to individual needs. | ||||||
21 | (7) If feasible, a hygienic, separate space for | ||||||
22 | individuals who need to administer a prescribed injectable | ||||||
23 | medication that can also be used as a quiet space to gather | ||||||
24 | composure in the event of an adverse on-site incident, | ||||||
25 | such as a nonfatal overdose. | ||||||
26 | (8) If feasible, access to on-site drug adulterant |
| |||||||
| |||||||
1 | testing supplies such as reagents, test strips, or | ||||||
2 | quantification instruments that provide critical real-time | ||||||
3 | information on the composition of substances obtained for | ||||||
4 | consumption. | ||||||
5 | (c) (Blank). Notwithstanding any provision of the Illinois | ||||||
6 | Controlled Substances Act, the Drug Paraphernalia Control Act, | ||||||
7 | or any other law, no employee or volunteer of or participant in | ||||||
8 | a program established under this Act shall be charged with or | ||||||
9 | prosecuted for possession of any of the following: | ||||||
10 | (1) Needles, hypodermic syringes, or other drug | ||||||
11 | consumption paraphernalia obtained from or returned, | ||||||
12 | directly or indirectly, to a program established under | ||||||
13 | this Act. | ||||||
14 | (2) Residual amounts of a controlled substance | ||||||
15 | contained in used needles, used hypodermic syringes, or | ||||||
16 | other used drug consumption paraphernalia obtained from or | ||||||
17 | returned, directly or indirectly, to a program established | ||||||
18 | under this Act. | ||||||
19 | (3) Drug adulterant testing supplies such as reagents, | ||||||
20 | test strips, or quantification instruments obtained from | ||||||
21 | or returned, directly or indirectly, to a program | ||||||
22 | established under this Act. | ||||||
23 | (4) Any residual amounts of controlled substances used | ||||||
24 | in the course of testing the controlled substance to | ||||||
25 | determine the chemical composition and potential threat of | ||||||
26 | the substances obtained for consumption that are obtained |
| |||||||
| |||||||
1 | from or returned, directly or indirectly, to a program | ||||||
2 | established under this Act.
| ||||||
3 | In addition to any other applicable immunity or limitation | ||||||
4 | on civil liability, a law enforcement officer who, acting on | ||||||
5 | good faith, arrests or charges a person who is thereafter | ||||||
6 | determined to be entitled to immunity from prosecution under | ||||||
7 | this subsection (c) shall not be subject to civil liability | ||||||
8 | for the arrest or filing of charges. | ||||||
9 | (d) Prior to the commencing of operations of a program | ||||||
10 | established under this Act, the governmental or | ||||||
11 | nongovernmental organization shall submit to the Illinois | ||||||
12 | Department of Public Health all of the following information: | ||||||
13 | (1) the name of the organization, agency, group, | ||||||
14 | person, or entity operating the program; | ||||||
15 | (2) the areas and populations to be served by the | ||||||
16 | program; and | ||||||
17 | (3) the methods by which the program will meet the | ||||||
18 | requirements of subsection (b) of this Section. | ||||||
19 | The Department of Public Health may adopt rules to | ||||||
20 | implement this subsection.
| ||||||
21 | (Source: P.A. 101-356, eff. 8-9-19.) | ||||||
22 | (410 ILCS 710/10 new) | ||||||
23 | Sec. 10. Dispensing of drug adulterant testing supplies. A | ||||||
24 | pharmacist or physician may dispense drug adulterant testing | ||||||
25 | supplies such as reagents, test strips, or quantification |
| |||||||
| |||||||
1 | instruments to any person. Drug adulterant testing supplies | ||||||
2 | dispensed under this Section must be stored at a pharmacy, | ||||||
3 | hospital, clinic, or other health care facility licensed under | ||||||
4 | State or federal law or at the medical office of a physician | ||||||
5 | and in a manner that limits access to the drug adulterant | ||||||
6 | testing supplies to pharmacists and physicians employed at the | ||||||
7 | pharmacy, hospital, clinic, or other health care facility, | ||||||
8 | medical office, and any person designated by the pharmacist or | ||||||
9 | physician. Drug adulterant testing supplies dispensed under | ||||||
10 | this Section at a retail store containing a pharmacy may be | ||||||
11 | dispensed only from the pharmacy department of the retail | ||||||
12 | store. | ||||||
13 | (410 ILCS 710/15 new) | ||||||
14 | Sec. 15. Waiver of criminal penalties. Notwithstanding any | ||||||
15 | provision of the Illinois Controlled Substances Act, the Drug | ||||||
16 | Paraphernalia Control Act, or any other law, no employee or | ||||||
17 | volunteer of or participant in a program established under | ||||||
18 | this Act or any employee or customer of a pharmacy, hospital, | ||||||
19 | clinic, or other health care facility or medical office | ||||||
20 | dispensing drug adulterant testing supplies in accordance with | ||||||
21 | Section 10 of this Act shall be charged with or prosecuted for | ||||||
22 | possession of any of the following: | ||||||
23 | (1) Needles, hypodermic syringes, or other drug | ||||||
24 | consumption paraphernalia obtained from or returned, | ||||||
25 | directly or indirectly, to a program established under |
| |||||||
| |||||||
1 | this Act. | ||||||
2 | (2) Residual amounts of a controlled substance | ||||||
3 | contained in used needles, used hypodermic syringes, or | ||||||
4 | other used drug consumption paraphernalia obtained from or | ||||||
5 | returned, directly or indirectly, to a program established | ||||||
6 | under this Act. | ||||||
7 | (3) Drug adulterant testing supplies such as reagents, | ||||||
8 | test strips, or quantification instruments obtained from | ||||||
9 | or returned, directly or indirectly, to a program | ||||||
10 | established under this Act or a pharmacy, hospital, | ||||||
11 | clinic, or other health care facility or medical office | ||||||
12 | dispensing such drug adulterant testing supplies in | ||||||
13 | accordance with Section 10. | ||||||
14 | (4) Residual amounts of a controlled substance used in | ||||||
15 | the course of testing the controlled substance to | ||||||
16 | determine the chemical composition and potential threat of | ||||||
17 | the substance obtained for consumption that is obtained | ||||||
18 | from or returned, directly or indirectly, to a program | ||||||
19 | established under this Act. | ||||||
20 | In addition to any other applicable immunity or limitation | ||||||
21 | on civil liability, a law enforcement officer who, acting on | ||||||
22 | good faith, arrests or charges a person who is thereafter | ||||||
23 | determined to be entitled to immunity from prosecution under | ||||||
24 | this Section shall not be subject to civil liability for the | ||||||
25 | arrest or filing of charges. |
| |||||||
| |||||||
1 | (410 ILCS 710/20 new) | ||||||
2 | Sec. 20. Confidentiality. | ||||||
3 | (a) Any record of a person that is created or obtained for | ||||||
4 | use by a needle and hypodermic syringe access program or by a | ||||||
5 | pharmacy, hospital, clinic, or other health care facility or | ||||||
6 | medical office in connection with the dispensing of drug | ||||||
7 | adulterant testing supplies in accordance with Section 10 must | ||||||
8 | be kept confidential and: | ||||||
9 | (1) is not open for public inspection or disclosure; | ||||||
10 | (2) must not be shared with any other person or entity | ||||||
11 | without the consent of the person to whom the record | ||||||
12 | relates; and | ||||||
13 | (3) is not discoverable or admissible during any legal | ||||||
14 | proceeding. | ||||||
15 | (b) A record described in subsection (a) must not be used: | ||||||
16 | (1) to initiate or substantiate any criminal charge | ||||||
17 | against a person who participates in the needle and | ||||||
18 | hypodermic syringe access program or who obtains drug | ||||||
19 | adulterant testing supplies from a pharmacy, hospital, | ||||||
20 | clinic, or other health care facility or medical office in | ||||||
21 | accordance with Section 10; or | ||||||
22 | (2) as grounds for conducting any investigation of a | ||||||
23 | person who participates in the needle and hypodermic | ||||||
24 | syringe access program or who obtains drug adulterant | ||||||
25 | testing supplies from a pharmacy, hospital, clinic, or | ||||||
26 | other health care facility or medical office in accordance |
| |||||||
| |||||||
1 | with Section 10. | ||||||
2 | (c) The staff and volunteers of a needle and hypodermic | ||||||
3 | syringe access program or a pharmacy, hospital, clinic, or | ||||||
4 | other health care facility or medical office dispensing drug | ||||||
5 | adulterant testing supplies in accordance with Section 10 | ||||||
6 | shall not be compelled to provide evidence in any criminal | ||||||
7 | proceeding conducted pursuant to the laws of this State | ||||||
8 | concerning any information that was entrusted to them or | ||||||
9 | became known to them through the program or through the | ||||||
10 | dispensing. | ||||||
11 | (d) The use of any personal information of (i) any person | ||||||
12 | who participates in a needle and hypodermic syringe access | ||||||
13 | program or obtains drug adulterant testing supplies from a | ||||||
14 | pharmacy, hospital, clinic, or other health care facility or | ||||||
15 | medical office in accordance with Section 10, or (ii) the | ||||||
16 | staff or volunteers of the needle and hypodermic syringe | ||||||
17 | access program or the pharmacy, hospital, clinic, or other | ||||||
18 | health care facility or medical office, in research and | ||||||
19 | evaluation, must be done in such a manner as to guarantee the | ||||||
20 | anonymity of the person. | ||||||
21 | (e) Aggregate data from a needle and hypodermic syringe | ||||||
22 | access program, including, without limitation, demographic | ||||||
23 | information, the number of clients contacted, and the types of | ||||||
24 | referrals may be made available to the public.
| ||||||
25 | Section 99. Effective date. This Act takes effect upon | ||||||
26 | becoming law.
|